• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

左心疾病相关肺动脉高压:表型与治疗。

Pulmonary hypertension associated to left heart disease: Phenotypes and treatment.

机构信息

University Cardiology Division, Pisa University Hospital and University of Pisa, Via Paradisa, 2, Pisa 56124, Italy.

University Cardiology Division, Pisa University Hospital and University of Pisa, Via Paradisa, 2, Pisa 56124, Italy.

出版信息

Eur J Intern Med. 2024 Nov;129:1-15. doi: 10.1016/j.ejim.2024.07.030. Epub 2024 Aug 1.

DOI:10.1016/j.ejim.2024.07.030
PMID:39095300
Abstract

Pulmonary hypertension associated to left heart disease (PH-LHD) refers to a clinical and haemodynamic condition of pulmonary hypertension associated with a heterogeneous group of diseases affecting any of the compartments that form the left ventricle and left atrium. PH-LHD is the most common cause of PH, accounting for 65-80 % of diagnoses. Based on the haemodynamic phase of the disease, PH-LDH is classified into three subgroups: postcapillary PH, isolated postcapillary PH and combined pre-postcapillary PH (CpcPH). Several signaling pathways involved in the regulation of vascular tone are dysfunctional in PH-LHD, including nitric oxide, MAP kinase and endothelin-1 pathways. These pathways are the same as those altered in PH group 1, however PH-LHD can heardly be treated by specific drugs that act on the pulmonary circulation. In this manuscript we provide a state of the art of the available clinical trials investigating the safety and efficacy of PAH-specific drugs, as well as drugs active in patients with heart failure and PH-LHD. We also discuss the different phenotypes of PH-LHD, as well as molecular targets and signaling pathways potentially involved in the pathophysiology of the disease. Finally we will mention some new emerging therapies that can be used to treat this form of PH.

摘要

与左心疾病相关的肺动脉高压(PH-LHD)是指一种与影响左心室和左心房任何部位的异质性疾病相关的肺动脉高压的临床和血液动力学状态。PH-LHD 是 PH 最常见的原因,占诊断的 65-80%。根据疾病的血液动力学阶段,PH-LDH 分为三组:毛细血管后 PH、孤立性毛细血管后 PH 和混合前毛细血管后 PH(CpcPH)。在 PH-LHD 中,参与血管张力调节的几个信号通路功能失调,包括一氧化氮、MAP 激酶和内皮素-1 通路。这些通路与 PH 组 1 中改变的通路相同,但 PH-LHD 几乎不能用作用于肺循环的特定药物治疗。在本文中,我们提供了关于正在进行的临床试验的最新情况,这些试验调查了 PAH 特异性药物以及对心力衰竭和 PH-LHD 患者有效的药物的安全性和疗效。我们还讨论了 PH-LHD 的不同表型,以及可能参与疾病病理生理学的分子靶点和信号通路。最后,我们将提到一些可用于治疗这种 PH 形式的新出现的治疗方法。

相似文献

1
Pulmonary hypertension associated to left heart disease: Phenotypes and treatment.左心疾病相关肺动脉高压:表型与治疗。
Eur J Intern Med. 2024 Nov;129:1-15. doi: 10.1016/j.ejim.2024.07.030. Epub 2024 Aug 1.
2
Left ventricular heart failure and pulmonary hypertension.左心室心力衰竭和肺动脉高压。
Eur Heart J. 2016 Mar 21;37(12):942-54. doi: 10.1093/eurheartj/ehv512. Epub 2015 Oct 27.
3
Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component.左心疾病所致肺动脉高压的临床表型和结局:毛细血管前成分的作用。
PLoS One. 2018 Jun 19;13(6):e0199164. doi: 10.1371/journal.pone.0199164. eCollection 2018.
4
[Pulmonary hypertension – a common condition in left heart disease].肺动脉高压——左心疾病中的常见病症
Lakartidningen. 2017 Dec 1;114:ER3E.
5
Pulmonary Hypertension Due to Left Heart Disease-A Practical Approach to Diagnosis and Management.左心疾病所致肺动脉高压的诊断与处理策略
Can J Cardiol. 2021 Apr;37(4):572-584. doi: 10.1016/j.cjca.2020.11.003. Epub 2020 Nov 17.
6
Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy.左心疾病所致肺动脉高压:诊断、病理生理学与治疗。
Hypertension. 2020 Jun;75(6):1397-1408. doi: 10.1161/HYPERTENSIONAHA.119.14330. Epub 2020 Apr 27.
7
Pulmonary hypertension associated with left heart disease.与左心疾病相关的肺动脉高压。
Semin Respir Crit Care Med. 2013 Oct;34(5):665-80. doi: 10.1055/s-0033-1356490. Epub 2013 Sep 13.
8
Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease.左心疾病相关肺动脉高压的诊断与管理要点。
JACC Heart Fail. 2024 Aug;12(8):1328-1342. doi: 10.1016/j.jchf.2024.04.031. Epub 2024 Jul 3.
9
Pulmonary hypertension associated with left-sided heart disease.与左心疾病相关的肺动脉高压。
Swiss Med Wkly. 2017 Jan 17;147:w14395. doi: 10.57187/smw.2017.14395. eCollection 2017.
10
Update in approaches to pulmonary hypertension because of left heart disease.左心疾病相关肺动脉高压治疗方法的新进展。
Curr Opin Pulm Med. 2022 Sep 1;28(5):337-342. doi: 10.1097/MCP.0000000000000891. Epub 2022 Jul 16.

引用本文的文献

1
Small vessels, big problem: a dive into the pulmonary microcirculation in pulmonary hypertension and methods for evaluation.小血管,大问题:深入探讨肺动脉高压中的肺微循环及其评估方法。
EBioMedicine. 2025 Jul 25;118:105867. doi: 10.1016/j.ebiom.2025.105867.
2
Hemodynamic Definitions, Phenotypes, Pathophysiology, and Evaluation of Pulmonary Hypertension Related to Left Heart Disease.与左心疾病相关的肺动脉高压的血流动力学定义、表型、病理生理学及评估
J Cardiovasc Dev Dis. 2025 Jun 22;12(7):238. doi: 10.3390/jcdd12070238.
3
Burden of pulmonary arterial hypertension in children globally, regionally, and nationally (1990-2021): results from the global burden of disease study.
1990 - 2021年全球、区域和国家层面儿童肺动脉高压疾病负担:全球疾病负担研究结果
Front Pediatr. 2025 Jun 30;13:1527281. doi: 10.3389/fped.2025.1527281. eCollection 2025.
4
Single nuclei RNA-sequencing unveils alveolar macrophages as drivers of endothelial damage in obese HFpEF-related pulmonary hypertension.单核RNA测序揭示肺泡巨噬细胞是肥胖型射血分数保留的心力衰竭相关肺动脉高压中内皮损伤的驱动因素。
Cardiovasc Diabetol. 2025 Jul 3;24(1):268. doi: 10.1186/s12933-025-02772-y.
5
Hydrogen sulfide as a new therapeutic target of pulmonary hypertension: an overview with update on immunomodulation.硫化氢作为肺动脉高压的新治疗靶点:免疫调节最新进展综述
Front Pharmacol. 2025 May 12;16:1510275. doi: 10.3389/fphar.2025.1510275. eCollection 2025.
6
Pulmonary hypertension aetiologies in different parts of the world.世界各地肺动脉高压的病因。
Int J Cardiol Congenit Heart Dis. 2025 Apr 15;20:100586. doi: 10.1016/j.ijcchd.2025.100586. eCollection 2025 Jun.
7
Emerging Mechanistic Insights and Therapeutic Strategies for Pulmonary Arterial Hypertension: A Focus on Right Ventricular Dysfunction and Novel Treatment Pathways.肺动脉高压的新兴机制见解与治疗策略:聚焦右心室功能障碍和新型治疗途径
Biomedicines. 2025 Mar 1;13(3):600. doi: 10.3390/biomedicines13030600.
8
The role of lactate metabolism and lactylation in pulmonary arterial hypertension.乳酸代谢和乳酸化在肺动脉高压中的作用。
Respir Res. 2025 Mar 12;26(1):99. doi: 10.1186/s12931-025-03163-3.
9
Perspectives on Sotatercept in Pulmonary Arterial Hypertension.司他特截用于肺动脉高压的前景
J Clin Med. 2024 Oct 28;13(21):6463. doi: 10.3390/jcm13216463.